The two companies stated in a statement that the FDA had asked for further information on the completed clinical trials but did not seek updated research results. In this regard, the two companies will continue to work hard to meet regulatory requirements and strive for production licenses.
Eliquis has a thrombolytic effect and will be mainly used to treat thrombus-induced arrhythmia. Sanford C. Bernstein & Co. Company analyst Tim Anderson believes that once the drug is approved for use, its annual market sales will be $2.5 billion by 2015.
Stevia sweeteners are derived from the leaves of the Stevia rebaudiana (Bertoni) plant, an herbal shrub native to South America. The stevia plant has been used for food and medicinal purposes for hundreds of years, and its leaves and crude extracts have been sold as dietary supplements. Purified extracts of the sweet substances found in the stevia leaf, called steviol glycosides, are considered to be generally recognized as safe (GRAS) by the U.S. Food and Drug Administration (FDA). However, whole stevia leaves and crude leaf extracts are not permitted to be sold as sweeteners in the U.S. because there is not enough toxicological information on these products, according to the FDA. Stevia sweeteners are made by extracting steviol glycosides from the leaves of the stevia plant and purifying them to remove some of the bitter attributes found in the crude extract.
Stevia
JINING USP INTERNATIONAL CO.,LTD. , https://www.uspintl.com